This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
By the subsequent Potsdam Agreement, the four Allied Powers asserted joint sovereignty over "Germany as a whole", defined as the totality of the territory within the occupation zones. Former German areas east of the rivers Oder and Neisse and outside of 'Germany as a whole' were officially separated from German sovereignty in August 1945 and transferred from Soviet military occupation to Polish and Soviet (in the case of the territory of Kaliningrad) civil administration, their Polish and Soviet status to be confirmed at a final Peace Treaty. Following wartime commitments by the Allies to the governments-in-exile of Czechoslovakia and Poland, the Potsdam Protocols also agreed to the 'orderly and humane' transfer to Germany as a whole of the ethnic German populations in Poland, Czechoslovakia and Hungary. Eight million German expellees and refugees eventually settled in West Germany. Between 1946 and 1949, three of the occupation zones began to merge. First, the British and American zones were combined into the quasi-state of Bizonia. Soon afterwards, the French zone was included into Trizonia. Conversely, the Soviet zone became East Germany. At the same time, new federal states (Länder) were formed in the Allied zones; replacing the geography of pre-Nazi German states such as the Free State of Prussia and the Republic of Baden, which had derived ultimately from former independent German kingdoms and principalities.
==== MeSH D12.776.220.525.475 – myosins ==== MeSH D12.776.220.525.475.100 – myosin heavy chains MeSH D12.776.220.525.475.200 – myosin light chains MeSH D12.776.220.525.475.300 – myosin subfragments MeSH D12.776.220.525.475.470 – myosin type i MeSH D12.776.220.525.475.475 – myosin type ii MeSH D12.776.220.525.475.475.124 – cardiac myosins MeSH D12.776.220.525.475.475.124.249 – atrial myosins MeSH D12.776.220.525.475.475.124.500 – ventricular myosins MeSH D12.776.220.525.475.475.249 – nonmuscle myosin type iia MeSH D12.776.220.525.475.475.500 – nonmuscle myosin type iib MeSH D12.776.220.525.475.475.750 – skeletal muscle myosins MeSH D12.776.220.525.475.475.875 – smooth muscle myosins MeSH D12.776.220.525.475.612 – myosin type iii MeSH D12.776.220.525.475.681 – myosin type iv MeSH D12.776.220.525.475.750 – myosin type v
A single dose of LSD (Definium Therapeutics's DT120 candidate) markedly reduced major depressive disorder symptoms versus placebo in a Phase 3 trial, with benefits lasting at least 12 weeks and no major safety concerns. LSD is a psychoplastogen, a compound capable of promoting rapid and sustained neural plasticity, an action that hypothetically might be involved in its therapeutic benefits. Preliminary evidence in humans suggests that a single dose of LSD may also temporarily benefit learning and memory. More research is needed to substantiate such notions. The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of psychedelics like LSD for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.
Sources: en.wikipedia.org
== Medical uses == Suvorexant is used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, in adults. At a dose of 15 to 20 mg and in terms of treatment–placebo difference, it reduces time to sleep onset by up to 10 minutes, reduces time awake after sleep onset by about 15 to 30 minutes, and increases total sleep time by about 10 to 20 minutes. A 2017 systematic review and meta-analysis of randomized controlled trials of suvorexant for insomnia likewise found that the medication improved subjective sleep onset, subjective total sleep time, and subjective sleep quality when assessed at one to three months of treatment. The effectiveness of approved doses of suvorexant (≤20 mg) in the treatment of insomnia is said to be modest. Network meta-analyses have assessed the sleep-promoting effects of suvorexant and have compared them to those of other orexin receptor antagonists like lemborexant and daridorexant as well as to other sleep aids including benzodiazepines, Z-drugs, antihistamines, sedative antidepressants (e.g., trazodone, doxepin, amitriptyline, mirtazapine), and melatonin receptor agonists. A major systematic review and network meta-analysis of insomnia medications published in 2022 found that suvorexant had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.31 (95% CITooltip confidence interval 0.01 to 0.62).
=== Carcinoma === Carcinoma is a type of cancer that occurs in epithelial cells. Transitional cell carcinoma (urothelial carcinoma) is the leading type of bladder cancer, occurring in 9 out of 10 cases. It is also the leading cause of cancer of the ureter, urethra, and urachus, and the second leading cause of cancer of the kidney. Transitional cell carcinoma can develop in two different ways. Should the transitional cell carcinoma grow toward the inner surface of the bladder via finger-like projections, it is known as papillary carcinoma. Otherwise, it is known as flat carcinoma. Either form can transition from non-invasive to invasive by spreading into the muscle layers of the bladder. Transitional cell carcinoma is commonly multifocal, more than one tumor occurring at the time of diagnosis. Transitional cell carcinoma can metastasize, or spread to other parts of the body via the surrounding tissues, the lymph system, and the bloodstream. It can spread to the tissues and fat surrounding the kidney, the fat surrounding the ureter, or, more progressively, lymph nodes and other organs, including bone. Common risk factors of transitional cell carcinoma include long-term misuse of pain medication, smoking, and exposure to chemicals used in the making of leather, plastic, textiles, and rubber. Transitional cell carcinoma patients have a variety of treatment options. These include nephroureterectomy, or the removal of kidney, ureter, and bladder cuff, and segmental resection of the ureter.
Less than 5% of the power consumed by a typical tungsten incandescent light bulb is converted into visible light, with most of the rest being emitted as invisible infrared radiation. Some applications make use of the emitted infrared radiation, such as heat lamps in incubators, lava lamps, Edison effect bulbs, and the Easy-Bake Oven toy. Quartz envelope halogen infrared heaters are used for industrial processes such as paint curing and space heating. Light bulbs are rated by their luminous efficacy, which is the ratio of the amount of visible light emitted (luminous flux) to the electrical power consumed. Luminous efficacy is measured in lumens per watt (lm/W). The luminous efficiency of a source is defined as the ratio of its luminous efficacy to the maximum possible luminous efficacy, which is 683 lm/W. An ideal white light source could produce about 250 lumens per watt, corresponding to a luminous efficiency of 37%. For a given quantity of light, an incandescent light bulb consumes more power and emits more heat than most other types of electric light. In buildings where air conditioning is used, incandescent lamps' heat output increases load on the air conditioning system. While heat from lights will reduce the need to run a building's heating system, the latter can usually produce the same amount of heat at lower cost than incandescent lights. The chart below lists the luminous efficacy and efficiency for several types of incandescent bulb. A longer chart in luminous efficacy compares a broader array of light sources.
=== PDCAAS === The earlier "modern" measurement is the PDCAAS of 1989. For protein digestibility it compares the amount of protein-nitrogen that goes into a rat and out of the rat through feces, with a correction for "metabolic fecal protein": the amount of protein that occurs in feces when the rat is on a protein-free diet. For the amino acid score, it considers the quantity of each essential amino acid in the food as a proportion of the food's protein content and compares this to nutritional recommendations for preschool-age kids. The amino acid score used is that of the lowest, or 'limiting', amino acid. The amino acid score is then multiplied with the fecal digestibility score to get an overall score between zero and one. The PDCAAS has a tendency to over-estimate digestibility, because it measures feces instead of what remains at the end of the small intestine, where most protein absorption is believed to occur. Antinutrient factors like phytic acid and trypsin inhibitors may decrease absorption of protein, as does the absorption of protein by gut bacteria in the test subject's large intestine. In addition, older rats show lower PDCAAS-estimated fecal digestibility compared to young rats when the protein source contains anti-nutritional factors.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.